Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression

Journal of Clinical Oncology

Volumn 26, Issue 20, 2008, Pages 3324-3330

  Anders, Carey K ^a   Hsu, David S ^a   Broadwater, Gloria ^a   Acharya, Chaitanya R ^a   Foekens, John A ^a   Zhang, Yi ^a   Wang, Yixin ^a   Marcom, P Kelly ^a   Marks, Jeffrey R ^a   Febbo, Phillip G ^a   Nevins, Joseph R ^a   Potti, Anil ^a   Blackwell, Kimberly L ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; MESSENGER RNA; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; AGE; ANALYSIS OF VARIANCE; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROBABILITY; PROSPECTIVE STUDY; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 49149119336     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2471     Document Type: Article

References (40)

1. Adami HO, Malker B, Holmberg L, et al: The relation between survival and age at diagnosis and breast cancer. N Engl J Med 315:559-563, 1986
2. El Saghir NS, Seoud M, Khalil MK, et al: Effects of young age at presentation on survival in breast cancer. BMC Cancer 6:194, 2006
3. Nixon AJ, Neuburg D, Hayes DF, et al: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I and II breast cancer. J Clin Oncol 12:888-894, 1994
4. Holli K, Isola J: Effect of age on the survival of breast cancer patients. Eur J Cancer 33:425-428, 1997
5. Kollias J, Elston CW, Ellis I, et al: Early onset breast cancer: Histopathological and prognostic considerations. Br J Cancer 75:1318-1323, 1997
6. Albain KS, Allred DC, Clark GM: Breast cancer outcomes and predictors of outcome: Are there age differentials? J Natl Cancer Inst Monogr 16:35-42, 1994
7. de la Rochefordiere A, Asselain B, Campana F, et al: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039-1043, 1993
8. Aebi S, Gelber S, Castiglione-Gertsch M, et al: Is chemotherapy alone adequate for young women with oestrogen receptor-positive breast cancer? Lancet 355:1869-1874, 2000
9. Chang HY, Nuyten DS, Sneedon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
10. Chang HY, Sneedon JB, Alizadeh AA, et al: Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLOS Biol 2:E7, 2004
11. Paik S, Shak S, Tang G, et al: A multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
12. Perou CM, Sorlie R, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000
13. Sorlie R, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implication. Proc Natl Acad Sci U S A 98:10869-10874, 2001
14. van de Vijver MJ, He YD, van't Veer IJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
15. van't Veer IJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome in breast cancer. Nature 415:530-536, 2002
16. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006
17. Bild AH, Guang U, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357, 2006
18. Wang Y, Klijn JG, Zhang Y, et al: Gene expression profiles to predict distant metastasis in lymphnode negative primary breast cancer. Lancet 365:671-679, 2005
19. Ivshina AV, George J, Senko O, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292-10301, 2006
20. Potti A, Dressman HK, Bild AH, et al: Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294-1300, 2006
21. Grady D: Management of menopausal symptoms. N Engl J Med 355:2338-2347, 2006
22. Subramanian A, Tamayo P, Mootha V, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550, 2005
23. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer, 2001, p 58
24. Gong Y, Yan K, Lin F, et al: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: A gene-expression profiling study. Lancet Oncol 8:203-211, 2007
25. Kim C, Tang G, Baehner F, et al: A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 3116)
26. Ahn S, Son B, Kim S, et al: Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea - A report from the Korean Breast Cancer Society. J Clin Oncol 25:2360-2368, 2007
27. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
28. Hartley M, McKinley B, Rogers E, et al: Differential expression of prognostic factors and effect on survival in young (≤ or =40) breast cancer patients: A case-control study. Am Surg 72:1189-1194, 2006
29. Agrup M, Stal O, Olsen K, et al: C-erb-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 63:23-29, 2000
30. Coussens L, Yang-Feng T, Liao Y, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
31. Honrado E, Benítez J, Palacios J: The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod Pathol 18:1305-1320, 2005
32. van der Groep P, Bouter A, van der Zanden R, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96:712-713, 2004
33. Carey L, Perou CM, Livasy C, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
34. Sorlie R, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
35. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007
36. Vleugel M, Greijer A, Shvarts A, et al: Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58:172-177, 2005
37. Wicha S: Clinical implications of the cancer stem cell hypothesis. Am Soc Clin Oncol Ed Book, 2007
38. Wang-Gohrke S, Becher H, Kreienberg R, et al: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12:269-272, 2002
39. Malone K, Daling J, Thompson J, et al: BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922-929, 1998
40. Langston A, Malone K, Thompson J, et al: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334:137-142, 1996